Tesla up 2% as Morgan Stanley raises price target on stock

Analysts at Morgan Stanley on Tuesday raised their price target on Tesla Inc. stock to $379, from $317. Tesla’s “rapidly growing infrastructure footprint” for electric cars sets the company apart from others, the analysts said. They kept their rating on the shares at their equivalent of neutral. The $379 price target represents an 8% upside to Tuesday’s prices and compares with an average of $315.48 according to FactSet. Last week, analysts at Nomura started covering Tesla with a $500 price target, sending the stock higher.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Dow, S&P 500, Nasdaq jump to fresh intraday records as energy shares rallies

U.S. stocks climbed on Tuesday at the open as the energy sector rallied and as the International Monetary Fund raised its outlook for global growth, reinforcing optimism about the health of the world economy that has helped drive equities to all-time highs. The Dow Jones Industrial Average advanced 78 points, or 0.4%, at 22,839, the S&P 500 index gained 10 points, or 0.4%, at 2,554, aided by a firm climb in the energy sector, measured by the Energy Select Sector SPDR ETF. Meanwhile, the Nasdaq Composite Index rose 27 points, or 0.4%, to 6,607. All three benchmarks notched intrady records in early Tuesday trade. The IMF said roughly 75% of the world’s economy is sharing in the acceleration, a broader recovery than any in a decade. But it warned that a too-quick tapering from quantitative-easing measures by the European Central Bank and China failing to get a handle on its credit growth as factors that could derail economic progress. In corporate news, Procter & Gamble Co. shares gained as the consumer-products giant held an annual general meeting where a proxy vote among shareholders will decide on whether Trian Fund Management LP’s chief executive officer, Nelson Peltz, gets a seat on the company’s board. Meanwhile, Wal-Mart Stores Inc. shares were leading blue-chip gains, up 2.9%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

UPDATE: Express Scripts shares drop 2.5% on $3.6 bln eviCore acquisition

Express Scripts Holding Company shares dropped 2.5% premarket on news that the company has agreed to buy privately-held medical benefit management company eviCore healthcare for $3.6 billion. The deal is expected to close in the fourth quarter and should grow Express Scripts’ adjusted diluted earnings-per-share in the first full year of operation, the company said. Express Scripts, the largest stand-alone pharmacy-benefits manager, said that the acquisition is “an attractive entry point into a growing market” and noted that eviCore manages medical benefits for 100 million people. The two companies will be “uniquely positioned” to improve health care outcomes, said eviCore Chief Executive John Arlotta. Express Scripts is one of several companies in the pharmaceutical drug supply chain that could be threatened by an entry from online retailer Amazon. A decision from Amazon is reportedly expected by Thanksgiving. Express Scripts shares have plummeted 4.2% over the last three months, compared with a 4.8% rise in the S&P 500 .

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Shares of MoviePass owner Helios & Matheson rocket 15% in premarket trade

Shares of data firm Helios & Matheson Analytics Inc. , the company with a majority ownership stake in movie-theater subscription service MoviePass, were up more than 15% in premarket trade on Tuesday after closing up roughly 34% during the previous session. CNA Finance, a group of traders; educators and venture capitalists, wrote in a release that investors are clearly clamoring to get their hands on a piece of MoviePass. “There’s no denying the success of the plan surrounding MoviePass that was put in place by Helios & Matheson Analytics,” the team at CNA Finance wrote. “Moving forward, the CNA Finance team will continue to follow [Helios & Matheson stock] incredibly closely. In particular, we’re interested in following the ongoing growth of MoviePass, as we believe that HMNY may have created a goldmine when they reduced the price of the service.” Shares of Helios & Matheson have gained more than 539% in the year to date and more than 750% in the last three months. By comparison, the S&P 500 index is up nearly 14% in the year and the Dow Jones Industrial Average is up more than 15%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Nvidia’s stock surges toward record high after unveiling of new self-driving taxi hardware

Shares of Nvidia Corp. shot up 3.6% toward a record high in premarket trade Tuesday, after the graphics chip maker unveiled new hardware to be used in self-driving taxis. The stock changed hands at $192.12 ahead of the open, above the Sept. 18 record close of $187.55 and all-time intraday high of $191.20 reached the same day. The new hardware, which is the size of a license plate and harnesses the equivalent of 100 servers in a data center, is dubbed Nvidia Drive PX Pegasus, and was unveiled at the GTC technology conference in Europe. Nvidia’s stock has already rocketed 74% year to date through Monday, while the PHLX Semiconductor Index has run up 32% and the S&P 500 has gained 14%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

UPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaboration

KalVista Pharmaceuticals Inc. shares surged 111% in premarket trade Tuesday on news that Merck has acquired a 9.9% ownership stake in the company for $9.1 million, at a price of $8.50 per share. Merck will also pay KalVista $37 million upfront for the option to acquire KalVista’s diabetic macular edema drug candidate, which the companies will collaborate to develop, and a similar option for other future oral diabetic macular edema compounds. KalVista is also eligible for additional payments that could total up to $715 million, and will receive tiered royalties on net sales. KalVista plans to pay for and organize the planned phase 2 trial for the diabetic macular edema treatment, KVD001, and for other such compounds through phase 2. Diabetic macular edema is a diabetes complication that can cause impaired vision or vision loss. KalVista shares were valued at $7.35 as of Monday’s close. Shares have lifted 0.3% over the last three months, compared with a 4.8% rise in the S&P 500 . Merck shares lifted 0.5% in premarket trade.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Tropical Storm Ophelia could become 9th hurricane of Atlantic season; poses no threat to land

Tropical Storm Ophelia has formed over the Atlantic and is expected to become a hurricane in a day or two, the National Hurricane Center said in an advisory. The storm was about 790 miles west southwest of the Azores and was moving southeast at 3 miles an hour. Ophelia currently poses no threat to land, but it would be ninth Atlantic hurricane of the season. The storm has maximum sustained winds of 50 miles an hour.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

Eli Lilly’s stock sinks after disappointing results from late-stage trial of cancer treatment

Shares of Eli Lilly & Co. sank 4.2% in premarket trade Tuesday, after disappointing drug trial results. The company said earlier that a phase 3 trial of its lung cancer treatment Verzenio failed to meet its primary endpoint of overall survival. The company said secondary endpoints of progression-free survival and overall response rate showed evidence of monotherapy activity. Lilly said it would submit the data for presentation at a medical meeting in 2018. “While the outcome is unfortunate for patients with KRAS-mutated, advanced lung cancer, we remain encouraged by the antitumor activity observed with abemaciclib in this form of lung cancer where few clinical advances have been achieved,” said Levi Garraway, senior vice president of global development and medical affairs. The stock has run up 18.4% year to date through Monday, while the SPDR S&P Pharmaceuticals ETF has gained 10.8% and the S&P 500 has rallied 13.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

J.C. Penney partners with ‘Black-ish’ actress Tracee Ellis Ross for holiday collection

J.C. Penney Co. Inc. said Tuesday that it has partnered with Tracee Ellis Ross, star of the show “Black-ish,” for a holiday capsule collection, available in stores and online starting November 12. The Tracee Ellis Ross for JCPenney collection will include women’s clothing, accessories, and home decor. Items are priced below $75. J.C. Penney recently announced a cookware and bakeware line with Ayesha Curry, chef, Food Network personality, and wife to NBA star Steph Curry. J.C. Penney shares are up 1.4% in premarket trading, and down 57.3% for the year so far. The S&P 500 index is up 13.7% for 2017 and the Dow Jones Industrial Average is up 15.2% for the period.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News

American Airlines stock surges after unit revenue outlook raised

Shares of American Airlines Group Inc. surged 3.3% in premarket trade Tuesday, after the air carrier raised its third-quarter growth outlook for total revenue per available seat miles (TRASM) to a range of 0.5% to 1.5% from the previous guidance range of flat to up 1.0%. The company now expects pre-tax margin, excluding special items, of 9.0% to 11.0% from 8.5% to 10.5%. Capacity for the third quarter is expected to be 64.6 billion available seat miles, up from 63.5 billion ASM in the sequential second quarter, then fall to 58.9 billion ASM in the fourth quarter. The company said it spent $362 million to repurchase 7.7 million shares during the third quarter. The stock has lost 3.9% over the past three months through Monday, while the NYSE Arca Airline Index has shed 6.8% and the S&P 500 has gained 4.8%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

…read more

From:: Stock Market News